ArticleJACC. Asia2026
Biological Age Acceleration and All-Cause Mortality in Moderate to Severe Aortic Valve Stenosis: A Prospective Cohort Study.
Article in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiological age acceleration (BAA) is a promising aging surrogate, but its prognostic value in moderate to severe aortic valve stenosis (AVS) remains undetermined.
objectivesIn this study, the authors sought to explore the association between BAA and all-cause mortality in patients with moderate to severe AVS.
methodsA total of 559 patients were selected in the ARISTOTLE (Aortic Valve Diseases Risk Factor Assessment and Prognosis Model Construction) study. BAA was measured with the use of clinical biomarkers based on the KDM-BA and PhenoAge algorithms. Cox regression, restricted cubic spline (RCS) regression, and incremental predictive value analyses were used to evaluate the association between BAA and mortality.
resultsAmong 559 patients (mean age 64.80 years, 315 [56.4%] male), there were 153 cases (27.4%) of all-cause mortality during median 35.50 months of follow-up (range: 18.47-57.03 months). Kaplan-Meier curves revealed significantly elevated mortality in the highest quartile of BAA for both measures (KDM-BA: 38.8% [HR: 2.72; 95% CI: 1.73-4.29]; PhenoAge: 41.1% [HR: 3.26; 95% CI: 2.01-5.27]; both log-rank P < 0.0001). After fully adjusting for confounders, each SD increase in BAA was significantly associated with higher mortality (KDM-BA acceleration: HR: 1.36 [95% CI: 1.15-1.61]; PhenoAge acceleration: HR: 1.35 [95% CI: 1.17-1.56]). RCS regression revealed a significant linear BAA-mortality relationship. The addition of BAA into the basic model for all-cause mortality improved C-statistics (both P < 0.001), continuous-free net reclassification improvement value (both P = 0.013), and integrated discrimination improvement value (both P < 0.05).
conclusionsBiomarker-derived BAA is independently associated with increased all-cause mortality in moderate to severe AVS patients, highlighting its potential as a prognostic indicator.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.